Drug Development

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

A new Concord research center combines patient care and clinical trials, promising to speed up breakthroughs for complex heart, kidney, and metabolic diseases.

With promising clinical data, Clarametyx promotes key executives to accelerate its novel attack on chronic respiratory disease biofilms. Jennifer Anderson reports.

With key hires from Flatiron and Syneos, Target RWE signals major scaling plans in the booming real-world evidence market under new ownership.

A novel transdermal curcumin gel shows significant pain reduction in a clinical trial, offering a potential non-oral alternative for millions with knee pain.

Abbisko's irpagratinib gets EMA Orphan Drug status, fast-tracking a precision therapy for a hard-to-treat liver cancer subgroup with unmet needs.

China’s top infant formula maker is rewriting the global playbook, using cutting-edge research and local insight to challenge established giants in Southeast Asia.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

After its pivotal trial for ersodetug missed its primary endpoint, Rezolute gets a rare nod from the FDA to submit full data, igniting new hope.

New research on ILUMYA, LEQSELVI, and WINLEVI shows sustained efficacy and faster results, aiming to transform treatment for millions of patients.

New 3-year trial data shows UCB's BIMZELX prevents painful flares in most HS patients, highlighting a critical window for early intervention.

The pharma firm hit pause on a crucial reverse stock split needed to keep its Nasdaq listing, citing "timing considerations" and raising investor questions.

A groundbreaking study of 78,000 people shows most with acne and psoriasis manage their conditions alone, outside the clinic. Here's what it means.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

Weave Bio forms a star-studded advisory board with leaders from Gilead and Takeda to navigate the high-stakes world of AI in drug development.

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.